Perceive Biotherapeutics Appoints Anne E. Fung MD as Chief Medical Officer to Drive Transformational Clinical Programs

Dr. Fung, a Genentech veteran, brings extensive clinical expertise and leadership to the Perceive Bio team and will lead clinical programs across the company’s extensive ophthalmology pipeline

SOUTH SAN FRANCISCO, CA., May 18, 2022 /PRNewswire/ — Perceive Biotherapeutics, a biotechnology company pioneering new technologies and therapeutics in ophthalmology, today announced the appointment of Anne E. Fung, MD, as Chief Medical Officer. Dr. Fung joins a team of dedicated scientists and ophthalmology leaders where she will be responsible for advancing Perceive Bio’s pipeline in ophthalmology and expanding its portfolio into adjacent areas of interest.

Perceive Bio, a biotechnology company is a pioneer in new technologies and therapeutics in ophthalmology.

Perceive Biotherapeutics Appoints Anne E. Fung MD as Chief Medical Officer to Lead Transformational Clinical Programs.

“It is an exciting time to join the leadership team of Perceive Bio, a group whose track record of success demonstrates their exceptional insight into pragmatically translating science into clinical development. I am invigorated to carry forward decades of groundbreaking research to clinical trials and patient care,” said Dr. Fung.

Perceive Biotherapeutics is focused on the discovery and development of transformative gene therapies and other therapies for eye diseases with high unmet need. Leveraging deep genetic insights, Perceive Bio researchers have discovered key protective biological targets that uniquely position the company to accelerate the development of cutting-edge therapies for programs that account for more than 50% of the causes of blindness currently incurable. Perceive Bio advances therapeutic programs in AMD, glaucoma and other undisclosed disease areas.

“dr. anne funk is a unique force in clinical leadership,” said K. Angela Macfarlane, CEO of Perceive Biotherapeutics. “She is dedicated to advancing science to help patients preserve their vision. As a practicing retinal specialist, Anne led multicenter researcher and industry sponsored trials before joining industry. We believe Perceive Bio’s pipeline of ophthalmic drugs and technology platforms, complemented by Anne’s leadership, positions us to transform care with protective therapeutics.”

“We look forward to working with Anne and the team at Perceive Bio,” said Jeffrey S. HeierMD, Director, Retina Research, Ophthalmology Consultants of Boston, and a member of Perceive Bio’s Medical Advisory Board. “His success in developing and launching breakthrough new therapies in ophthalmology is well recognized. Genetically informed and supported therapies are important and have the potential to have a significant impact in our spectrum of patient care.”

Dr. Fung joins Perceive Biotherapeutics after eight years of leadership at Genentech, a member of the Roche Group. During her tenure, she led the US Medical Affairs Ophthalmology team to advance clinical research in AMD, diabetic eye disease and other eye conditions with an extension of Lucentis to lampalizumab (GA), faricimab (DME/AMD) and the Port Delivery System (AMD). /DME/DR). In 2019, she was selected to become the Port Delivery System Global Development Manager, where she led the team through key aspects of development and through Phase 3 trials of the world’s first long-acting neovascular treatment. AMD action that received FDA approval in 2021 (SUSVIMO ®). For two decades, Anne has pursued a passion for research in age-related macular degeneration and ophthalmology in academia, private practice, and the biotech industry with US and global collaborators. His research focuses on RPE transplantation, cataract biology, real-time OCT imaging observations of the effects of anti-VEGF on neovascular AMD, and clinical applications of Lucentis worldwide, resulting in multiple publications, presentations and book chapters that have helped shape the practice of care today. for neovascular AMD worldwide.

Dr. Fung is active in the clinical practice of medical retina in San Francisco and holds the Research Chair in the Ophthalmology Resident Research Program at California Pacific Medical Center. Graduated from Wellesley College and Cornell University Medical College, Anne completed her residency in ophthalmology at Stanford University Medical Center and a medical retina fellowship at Bascom Palmer Eye Institute in Miami.

“I have been passionate about retinal research and finding new solutions for over 20 years,” said Dr. Fung. “I see key pieces of science coming together at Perceive Bio…to bring even more hope and vision to patients around the world.”

About Perceive Biotherapeutics

Perceive Biotherapeutics is advancing a deep and diverse pipeline of treatment targets and modalities across multiple therapeutic verticals, with leading pipeline programs in ophthalmology. Perceive was founded on compelling research elucidating two novel protective biology for the treatment of retinal blindness, developed from fundamental collaborations in genetic science and target validation. The company is backed by Deerfield Management and will raise a Series B later this year. For more information, visit

Anne E. Fung, MD

Anne E. Fung, MD



View original content to download multimedia: -clinical-programs-301550149.html

SOURCE Perceive Biotherapeutics, Inc.